Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Florence Ader; Maude Bouscambert-Duchamp; Maja Hites; Bernd Lamprecht; et al.

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial

Florence Ader
, Maude Bouscambert-Duchamp
, Maja Hites
, Bernd Lamprecht
, et al.

Universitätsklinik für Innere Medizin 4 - Pneumologie und Infektiologie

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

Originalsprache	Englisch
Seiten (von - bis)	209-221
Seitenumfang	13
Fachzeitschrift	Lancet Infectious Diseases
Volume	22
Ausgabenummer	2
Publikationsstatus	Veröffentlicht - Feb. 2022

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gute Gesundheit und Wohlergehen

Wissenschaftszweige

302030 Innere Medizin
302068 Pulmologie

Andere Dateien und Links

Verknüpfung zur Publikation in Scopus

Dieses zitieren

@article{8624d055a12e4ad69695797c02061da3,

title = "Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial",

author = "Florence Ader and Maude Bouscambert-Duchamp and Maja Hites and Bernd Lamprecht and \{et al.\}",

year = "2022",

month = feb,

language = "English",

volume = "22",

pages = "209--221",

journal = "Lancet Infectious Diseases",

number = "2",

}

Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. / Ader, Florence; Bouscambert-Duchamp, Maude; Hites, Maja et al.
in: Lancet Infectious Diseases, Volume 22, Nr. 2, 02.2022, S. 209-221.

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

TY - JOUR

T1 - Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy)

T2 - a phase 3, randomised, controlled, open-label trial

AU - Ader, Florence

AU - Bouscambert-Duchamp, Maude

AU - Hites, Maja

AU - Lamprecht, Bernd

AU - et al., null

PY - 2022/2

Y1 - 2022/2

UR - https://www.scopus.com/pages/publications/85123728033

M3 - Article

C2 - 34534511

VL - 22

SP - 209

EP - 221

JO - Lancet Infectious Diseases

JF - Lancet Infectious Diseases

IS - 2

ER -